The AI IPO I'm Most Excited About (And No, It's Not OpenAI, Anthropic or xAI)

Cerebras is expected to IPO at roughly $23–26 billion and could debut as soon as this year (author suggests possibly spring 2026). The piece highlights mega AI IPO candidates (OpenAI, Anthropic, xAI/SpaceX) that could reach valuations near or above $1 trillion and materially alter S&P 500/Nasdaq composition; the Nasdaq 100 may already offer ~4–5% exposure to the largest upcoming AI IPOs. Recommendation: consider selective exposure to AI-chip IPOs like Cerebras versus broad index exposure, acknowledging timing and post-IPO performance uncertainty.

Analysis

The likely arrival of multiple very large AI issuers is a structural reweighting event: a single $1T+ market-cap entrant can claim 2–4% of a cap-weighted large-cap index on inclusion, forcing passive vehicles to buy size into an already crowded tape and compressing forward returns for incumbent mega-caps. That mechanical flow will amplify short-term volatility around listings and index rebalance windows (weeks → months), create transient liquidity gaps in mid-cap pools, and raise the cost of portfolio hedging as passive trackers bid up close substitutes.

At the supply-chain level, a tilt toward novel, larger-form-factor accelerators shifts capex from GPU inventories to specialized packaging, HBM stacks, and datacenter power/cooling upgrades — a multi-year capex reallocation for hyperscalers and enterprises. This reallocates margin pools: cloud providers that secure first-mover access to novel accelerators (via supply agreements or in-house silicon) will capture outsized services revenue and lock customers into higher-margin managed offerings, while traditional GPU suppliers face a cyclical destocking risk even if their long-run TAM grows.

Execution risk is binary and timeline-dependent: near-term IPO pricing and lockup expiries (0–6 months) will drive most volatility; medium-term (6–24 months) index inclusion and adoption outcomes determine winners. Tail risks include delayed enterprise model adoption, regulatory scrutiny on AI compute exports, and supplier consolidation that could negate first-mover hardware advantages. Practically, this argues for staged, event-driven exposure and hedges that target rebalance windows rather than naïve buy-and-hold allocations into headline IPOs.

Key Decisions for Investors

• Overweight AMZN (AWS exposure) vs underweight AAPL: increase AMZN exposure by +1–2% NAV funded by reducing AAPL by the same amount; express via buy-write/vertical call spreads on AMZN with 9–18 month expiries to cap cost. R/R: capture cloud services upside if hyperscalers lock new accelerator supply, asymmetric payoff if AMZN secures multi-year deals; downside limited to premium paid (~1–2% NAV).
• Hedge index-concentration reweighting: purchase a Nasdaq-100 or SPY put spread (6–12 month expiry, 8–12% OTM protection) sized to cover 1–2% NAV during anticipated IPO inclusion windows. R/R: small premium (0.5–1% NAV) protects against 10–20% drawdowns from forced selling and sentiment unwinds around listings.
• Small, staged allocation to specialist AI-chip IPOs: limit total exposure to 0.5–1% NAV per deal, tranche buys (pre-list at limit, average in at 4–8 weeks post-IPO and at lockup expiry). R/R: high idiosyncratic upside if adoption accelerates; downside capped by strict stop-loss (30–50%) and size discipline.
• Event-driven AMZN catalyst trade: if AMZN announces exclusive multi-year supply partnerships with next-gen accelerator vendors, add AMZN LEAPS (18–24 months) or convert current exposure into a 1:1 synthetic long (buy call/sell put) to magnify upside capture. R/R: levered upside to AWS monetization with known event trigger; full downside if cloud margins compress—keep position size <3% NAV.